Paper17554384
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM and 6 others. Leukemia, 2007. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Papers, record 17554384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17554384
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
- PubMed
Topics29
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biphenyl Compounds | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Leukemia, Myeloid | Major topic |
| Nitrophenols | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Sulfonamides | Major topic |
| fms-Like Tyrosine Kinase 3 | Major topic |
| Acute Disease | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Apoptosis | |
| Blotting, Western | |
| Cell Proliferation | |
| Cells, Cultured | |
| Flow Cytometry | |
| Humans | |
| Karyotyping | |
| Middle Aged | |
| Molecular Mimicry | |
| Myeloid Cell Leukemia Sequence 1 Protein | |
| Neoplasm Proteins | |
| Peptide Fragments | |
| Piperazines | |
| Proto-Oncogene Proteins | |
| STAT5 Transcription Factor | |
| Signal Transduction | |
| Trans-Activators | |
| bcl-X Protein |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12124170 | Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. | Cancer Cell | 2002 | https://conductscience.org/library/papers/12124170 | PubMed |
| 2 | 9525737 | Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. | Oncogene | 1998 | https://conductscience.org/library/papers/9525737 | PubMed |
| 3 | 14654525 | An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14654525 | PubMed |
| 4 | 15626746 | Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. | Blood | 2005 | https://conductscience.org/library/papers/15626746 | PubMed |
| 5 | 11146161 | Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. | Exp Hematol | 2000 | https://conductscience.org/library/papers/11146161 | PubMed |
| 6 | 16166262 | miR-15 and miR-16 induce apoptosis by targeting BCL2. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16166262 | PubMed |
| 7 | 15902208 | An inhibitor of Bcl-2 family proteins induces regression of solid tumours. | Nature | 2005 | https://conductscience.org/library/papers/15902208 | PubMed |
| 8 | 17234790 | Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. | Cancer Res | 2007 | https://conductscience.org/library/papers/17234790 | PubMed |
| 9 | 8943060 | The AML1/ETO fusion protein activates transcription of BCL-2. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8943060 | PubMed |
| 10 | 16997913 | Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16997913 | PubMed |
| 11 | 12842996 | Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. | Blood | 2003 | https://conductscience.org/library/papers/12842996 | PubMed |
| 12 | 12951584 | The role of FLT3 in haematopoietic malignancies. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12951584 | PubMed |
| 13 | 17097561 | The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Cancer Cell | 2006 | https://conductscience.org/library/papers/17097561 | PubMed |
| 14 | 16556074 | MicroRNAs as a potential magic bullet in cancer. | Future Oncol | 2006 | https://conductscience.org/library/papers/16556074 | PubMed |
| 15 | 12406902 | The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. | Blood | 2003 | https://conductscience.org/library/papers/12406902 | PubMed |
| 16 | 15901672 | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. | Genes Dev | 2005 | https://conductscience.org/library/papers/15901672 | PubMed |
| 17 | 12890867 | Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12890867 | PubMed |
| 18 | 16857985 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. | Blood | 2006 | https://conductscience.org/library/papers/16857985 | PubMed |
| 19 | 17016430 | A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Oncogene | 2007 | https://conductscience.org/library/papers/17016430 | PubMed |
| 20 | 15459012 | A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. | Blood | 2005 | https://conductscience.org/library/papers/15459012 | PubMed |
Cited by50
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42630653 | Targeting FLT3 in Acute Myeloid Leukemia: Structural Insights and Key Challenges. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42630653 | PubMed |
| 41942459 | Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/41942459 | PubMed |
| 41937490 | Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/41937490 | PubMed |
| 38112995 | FLT3 targeting in the modern era: from clonal selection to combination therapies. | Int J Hematol | 2024 | https://conductscience.org/library/papers/38112995 | PubMed |
| 38007585 | TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. | Leukemia | 2024 | https://conductscience.org/library/papers/38007585 | PubMed |
| 37958832 | AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37958832 | PubMed |
| 37760544 | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37760544 | PubMed |
| 36293564 | Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36293564 | PubMed |
| 36185253 | Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. | Front Oncol | 2022 | https://conductscience.org/library/papers/36185253 | PubMed |
| 35565314 | Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35565314 | PubMed |
| 35417742 | Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. | Exp Hematol | 2022 | https://conductscience.org/library/papers/35417742 | PubMed |
| 34203664 | Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34203664 | PubMed |
| 33598693 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. | Blood | 2021 | https://conductscience.org/library/papers/33598693 | PubMed |
| 33425766 | FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. | Front Oncol | 2020 | https://conductscience.org/library/papers/33425766 | PubMed |
| 33121874 | Extinguishing the Embers: Targeting AML Metabolism. | Trends Mol Med | 2021 | https://conductscience.org/library/papers/33121874 | PubMed |
| 32722298 | Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | Biomedicines | 2020 | https://conductscience.org/library/papers/32722298 | PubMed |
| 31717784 | Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31717784 | PubMed |
| 31632141 | Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31632141 | PubMed |
| 30972300 | The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome. | Front Oncol | 2019 | https://conductscience.org/library/papers/30972300 | PubMed |
| 30800259 | Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. | Ther Adv Hematol | 2019 | https://conductscience.org/library/papers/30800259 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| BCL2L1 | 598 | PubTator's text mining | https://conductscience.org/library/genes/598 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| MCL1 | 4170 | PubTator's text mining | https://conductscience.org/library/genes/4170 | NCBI Gene |
| STAT5A | 6776 | PubTator's text mining | https://conductscience.org/library/genes/6776 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17554384
GET https://conductscience.org/api/papers/v1/17554384/references?page=2